Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buparlisib - Adlai Nortye

Next Previous
X
Search
Drug Profile

Buparlisib - Adlai Nortye

Alternative Names: AN 2025; BKM-120; BKM120-AAA; Buparlisib hydrochloride; NVP-BKM120

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Adlai Nortye; Array BioPharma; Canadian Cancer Society Research Institute; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Hospices Civils de Lyon; Indiana University; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); NCIC Clinical Trials Group; Novartis; Novartis Oncology; Ohio State University; Paoli-Calmettes-institute; Sarah Cannon Research Institute; Stanford University; University of California at San Francisco
  • Class Amines; Antineoplastics; Morpholines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Preclinical Chronic myeloid leukaemia
  • Discontinued B-cell lymphoma; Basal cell cancer; Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; CNS cancer; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Gastrointestinal stromal tumours; Glioblastoma; Haematological malignancies; Leukaemia; Malignant melanoma; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Thymoma; Thyroid cancer; Ureteral neoplasms; Urethral cancer

Most Recent Events

  • 16 Jul 2024 Discontinued - Phase-I for B-cell lymphoma (Second-line therapy or greater, Recurrent) in USA (PO) prior to July 2024 (Novartis pipeline, July 2024) (Adlai Nortye pipeline, July 2024)
  • 16 Jul 2024 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) prior to July 2024 (Novartis pipeline, July 2024) (Adlai Nortye pipeline, July 2024)
  • 16 Jul 2024 Discontinued - Phase-I for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) prior to July 2024 (Novartis pipeline, July 2024) (Adlai Nortye pipeline, July 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top